文献速递淋巴瘤造血干细胞移植与细胞治疗

接受异基因造血干细胞移植的成人T细胞淋巴母细胞淋巴瘤的综合风险分层

Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
PubMed 文献 · Br J Haematol · 2025-08-26

这项多中心回顾性研究纳入104例接受异基因造血干细胞移植的完全代谢缓解成人T细胞淋巴母细胞淋巴瘤患者,评估移植前Deauville评分,并构建整合Deauville评分、免疫表型和供者类型的风险模型。Deauville评分3分患者2年总生存、无进展生存和复发均较差,该模型可区分低、中、高风险组,C指数为0.706。

要点

  • 移植前Deauville评分3分患者2年总生存、无进展生存较差且复发率较高。
  • 多因素分析显示移植前Deauville评分、免疫表型和供者类型是移植后复发的独立危险因素。
  • 新风险模型将患者分为低危66.0%、中危21.3%和高危12.7%,对总生存、无进展生存和复发的区分均有统计学意义。

核心结论

  • 研究提出一种可用于识别高危T细胞淋巴母细胞淋巴瘤患者以制定移植后个体化策略的临床工具。

研究设计与样本

  • 多中心回顾性研究,纳入104例接受异基因造血干细胞移植的完全代谢缓解成人T细胞淋巴母细胞淋巴瘤患者。

主要发现

  • Deauville评分3分患者2年总生存为70.5%,Deauville评分1-2分患者为77.4%和86.8%(p < 0.001)。
  • Deauville评分3分患者2年无进展生存为51.5%,Deauville评分1-2分患者为73.0%和81.1%(p < 0.001)。
  • Deauville评分3分患者复发率为42.1%,Deauville评分1-2分患者为15.4%和9.8%(p < 0.001)。
  • 多因素分析确定移植前Deauville评分、免疫表型和供者类型是移植后复发的独立危险因素,据此构建的风险模型将患者分为低危66.0%、中危21.3%和高危12.7%,对总生存、无进展生存和复发的区分均有统计学意义(p < 0.001),C指数为0.706。
  • 内部验证证实该风险分层模型具有良好的区分度、校准度和临床获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse remains the primary cause of transplant failure in T-cell lymphoblastic lymphoma (T-LBL) after allogeneic haematopoietic stem cell transplantation (allo-HSCT), yet prognostic data are scarce. We conducted a multicentre retrospective study of 104 adult T-LBL patients in complete metabolic remission (CMR) undergoing allo-HSCT. Pretransplant Deauville score (DS) was evaluated, and a risk model integrating DS, immunophenotype and donor type was developed. Patients with DS of 3 had significantly inferior 2-year overall survival (OS) (70.5% vs. 77.4% vs. 86.8%, p < 0.001), progression-free survival (PFS) (51.5% vs. 73.0% vs. 81.1%, p < 0.001) and higher relapse rates (42.1% vs. 15.4% vs. 9.8%, p < 0.001) compared to DS of 1-2. Multivariable analysis identified pretransplant DS, immunophenotype and donor type as independent risk factors for post-transplant relapse. These variables were integrated to construct a novel risk model stratifying patients into low- (66.0%), intermediate- (21.3%) and high-risk (12.7%) groups, strongly discriminating OS (p < 0.001), PFS (p < 0.001) and relapse (p < 0.001), with a C-index of 0.706. Internal validation confirmed that the risk stratification model had good discrimination, calibration and clinical benefit. Our findings propose a clinically actionable tool to identify high-risk T-LBL patients for tailored post-transplant strategies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yu F, Yu X, Hu X, et al. Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2025. PMID: 40856278. doi:10.1111/bjh.70102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。